Xenogenics Mot - C 3ml/60mg

Mitochondrial-derived peptide consisting of 16 amino acids naturally encoded by mitochondrial DNA.

Investigated for its role in supporting cellular energy metabolism and metabolic homeostasis.

Functions as an exercise mimetic by activating pathways associated with physical activity and endurance adaptation.

Activates AMP-activated protein kinase (AMPK), a key regulator of energy balance and metabolic function.

Supports efficient glucose uptake and utilisation within cells.

Promotes metabolic flexibility by helping the body adapt between carbohydrate and fat metabolism.

Targets skeletal muscle tissue, supporting adaptation to metabolic stress and energy demands.

May influence nuclear gene expression involved in cellular stress responses and metabolic resilience.

Studied for its potential effects on insulin sensitivity and healthy body composition.

Growing area of research in healthy ageing and age-related declines in physical performance.

Convenient multi-dose pen design for accurate and consistent administration.

Ready-to-use format requiring minimal preparation compared to traditional vial systems.

Precision dosing allows for greater ease of use within structured research protocols.

Manufactured under the Xenogenics brand philosophy of innovation, convenience, and premium peptide delivery systems.

Beginner Protocol

• 
  Dose: 5 mg
  
• 
  Frequency: Once weekly
  
• 
  Duration: 4–8 weeks
  

Performance & Body Composition Research Protocol

• 
  Dose: 5 mg
  
• 
  Frequency: Twice weekly
  
• 
  Total Weekly Dose: 10 mg
  
• 
  Duration: 4–8 weeks
  

Timing

• 
  Administer in the morning.
  
• 
  Commonly utilised 30–60 minutes before exercise to investigate exercise-mimetic effects.
  

Administration Route

• 
  Subcutaneous injection.
  

Cycling

• 
  Typical cycles:
  
  
  4–8 weeks on
  
  
  2–4 weeks off
  
  
  

Current literature suggests intermittent cycling due to the peptide's influence on AMPK signalling pathways.

What is MOTS-c?

MOTS-c is a naturally occurring mitochondrial-derived peptide consisting of 16 amino acids. It plays a role in regulating metabolism and cellular energy balance.

What does the Xenogenics MOT-C Pen contain?

The pen contains MOTS-c formulated in a convenient multi-dose delivery device intended for research applications.

How does MOTS-c work?

MOTS-c activates pathways such as AMP-activated protein kinase (AMPK), helping cells adapt to metabolic stress and improve energy utilisation.

Why is MOTS-c called an "exercise mimetic"?

Research suggests MOTS-c triggers some of the same metabolic pathways activated during exercise, potentially improving metabolic flexibility and endurance capacity.

What areas of research involve MOTS-c?

Researchers are investigating MOTS-c in relation to:

• 
  Metabolic health
  
• 
  Glucose regulation
  
• 
  Mitochondrial function
  
• 
  Healthy ageing
  
• 
  Exercise physiology
  
• 
  Body composition
  
• 
  Insulin sensitivity
  

Is MOTS-c FDA-approved?

No. MOTS-c has not been approved by the FDA for therapeutic use and remains an investigational peptide.

Are there human studies on MOTS-c?

Human data remain limited. Most evidence comes from animal studies and investigations involving MOTS-c analogues. Additional clinical research is required to establish long-term efficacy and safety.

Can MOTS-c replace exercise?

No. Although MOTS-c may activate exercise-related pathways, it does not replicate the full cardiovascular, musculoskeletal, and neurological benefits associated with regular physical activity.

What side effects have been reported?

Reported adverse effects in observational settings are generally mild and may include:

• 
  Injection-site irritation
  
• 
  Temporary fatigue
  
• 
  Mild nausea
  

Long-term safety data for native MOTS-c are currently unavailable.

Is MOTS-c banned in professional sport?

Yes. MOTS-c is prohibited under the World Anti-Doping Agency (WADA) regulations due to its potential performance-enhancing effects.

MOTS-c was first identified in 2015 as one of the first biologically active peptides encoded by mitochondrial DNA. Research demonstrated its ability to prevent diet-induced metabolic dysfunction and improve insulin sensitivity in animal models. Subsequent studies showed enhanced physical performance and improved metabolic resilience in ageing mice following MOTS-c administration. These findings have positioned MOTS-c as one of the most promising mitochondrial-derived peptides currently under investigation.

Disclaimer: Xenogenics MOT-C Pen products are intended strictly for laboratory and research use. They are not intended for human consumption or therapeutic application.